

The listing of the claims will replace all prior versions, and listings, of the claims in the application.

LISTING OF THE CLAIMS

1. (previously presented) A method for detecting *in vivo* CCI-779 activity in a patient having renal cell carcinoma (RCC), the method comprising:

(a) generating an expression profile of at least one CCI-779 activity gene selected from Table 5 in a peripheral blood sample obtained from the patient having RCC and at a stage of treatment with CCI-779;

(b) comparing the expression profile of the at least one CCI-779 activity gene generated in step (a) to a reference expression profile of said at least one CCI-779 activity gene; and

(c) detecting *in vivo* CCI-779 activity in the patient based on the comparison result from step (b), wherein:

(i) a statistically significant change in the expression profile of said at least one CCI-779 activity gene compared to the reference expression profile is indicative of the *in vivo* CCI-779 activity, and

(ii) the reference expression profile is a baseline-expression profile of said at least one CCI-779 activity gene in a peripheral blood sample isolated from one or more patients before CCI-779 treatment.

2 - 5. (cancelled)

6. (withdrawn – previously presented) The method according to claim 1, wherein said at least one CCI-779 activity gene includes at least two genes selected from Table 5.

7. (currently amended) The method according to claim 1, wherein the peripheral blood sample of step (a) is a whole blood sample.

8. (cancelled)

9. (previously presented) The method according to claim 1, wherein the expression profile of the at least one CCI-779 activity gene generated in step (a) is determined by reverse-transcription polymerase chain reaction (RT-PCR) or immunoassays.

10 – 16. (canceled)

17. (Currently amended) A method for identifying genes modulated by CCI-779, the method comprising:

- (a) obtaining a peripheral blood sample from a patient having renal cell carcinoma (RCC) and at a stage of treatment with CCI-779;
- (b) generating an expression profile of the peripheral blood sample obtained in step (a) and;
- (c) comparing said expression profile generated in step (b) to a reference expression profile of a reference peripheral blood sample ~~from said patient~~ to identify one or more differentially expressed genes, wherein the reference peripheral blood sample is isolated from one or more patients before CCI-779 treatment.

18. (withdrawn) A kit comprising a plurality of polynucleotides, wherein each of said polynucleotides is capable of hybridizing under stringent or nucleic acid array hybridization conditions to an RNA transcript, or the complement thereof, of a different respective gene selected from Table 5.

19. (withdrawn) A kit comprising a plurality of antibodies, wherein each of said antibodies is capable of binding to a polypeptide encoded by a different respective gene selected from Table 5.

20. (withdrawn) A nucleic acid array comprising polynucleotide probes, wherein a substantial portion of all polypeptide probes on the nucleic acid array can hybridize under stringent or nucleic acid array hybridization conditions to RNA transcripts, or the complements thereof, of genes selected from Table 5.

21. (previously presented) The method according to claim 1, wherein the at least one CCI-779 activity gene comprises profilin 1.

22. (previously presented) The method according to claim 1, wherein the stage of treatment with CCI-779 is 8 weeks after initiation of CCI-779 treatment.

23. (previously presented) The method according to claim 1, wherein the stage of treatment with CCI-779 is 16 weeks after initiation of CCI-779 treatment.

24. (previously presented) The method according to claim 17, wherein the reference expression profile is a baseline expression profile of a peripheral blood sample obtained from said patient before CCI-779 treatment.

25. (cancelled)

26. (previously presented) The method according to claim 17, wherein the stage of treatment with CCI-779 is 8 weeks after initiation of CCI-779 treatment.

27. (previously presented) The method according to claim 17, wherein the stage of treatment with CCI-779 is 16 weeks after initiation of CCI-779 treatment.